|Tested species reactivity||Human|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||White blood cells.|
|Contains||0.08% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Human CD10, also known as common acute lymphoblastic leukemia (CALLA), has been shown to react with TdT+ lymphoblastic leukemia, follicular germinal cell lymphoma, Burkittís lymphoma and chronic myelocytic leukemia. CD10 also marks normal early lymphoid progenitor cells, immature B-cells in adult bone marrow and germinal cells in normal tonsil and normal lymphoid tissue. It is also expressed in some non-lymphoid tissues such as fibroblasts, breast myoepithelium and brush border of kidney. CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lamda light chains. It appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation. It is expressed in all B cell precursor leukemias.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.